5 Investors to Follow Other Than Warren Buffett
There is no doubt that Warren Buffett is one of…
Sell
38
BMRA Quote, Financials, Valuation and Earnings
Last price:
$3.54
Seasonality move
:
0%
Day range:
$3.27 - $3.62
52-week range:
$1.93 - $10.16
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
1.33x
P/B ratio:
1.59x
Volume:
25.9K
Avg. volume:
40.9K
1-year change:
-26.69%
Market cap:
$8.8M
Revenue:
$5.4M
EPS (TTM):
-$2.32
Analysts' Opinion
-
Consensus RatingNo consensus rating exists at this time due to lack of analyst coverage.
-
Price Target UpsideNo price target exists because of limited analyst coverage.
-
Price Target DownsideSimilarly, at this time, analysts have not provided a price target so downside risk can't be assessed accurately at this time.
Fair Value
-
According to the consensus of 0 analysts, Biomerica has 2905.78% upside to fair value with a price target of -- per share.
BMRA vs. S&P 500
-
Over the past 5 trading days, Biomerica has underperformed the S&P 500 by -3.5% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Biomerica does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Biomerica has grown year-over-year revenues for 4 quarters straight. In the most recent quarter Biomerica reported revenues of $1.1M.
Earnings Growth
-
Biomerica has grown year-over-year earnings for 1 quarter straight. In the most recent quarter Biomerica reported earnings per share of -$0.48.
Enterprise value:
5.8M
EV / Invested capital:
1.04x
Price / LTM sales:
1.33x
EV / EBIT:
--
EV / Revenue:
1.01x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-1.34x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$765K
Return On Assets:
-57.58%
Net Income Margin (TTM):
-85.42%
Return On Equity:
-79.79%
Return On Invested Capital:
-79.79%
Operating Margin:
-108.13%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-02-28 | 2024-02-28 | 2025-02-28 | 2024-02-28 | 2025-02-28 | |
| Income Statement | ||||||
| Revenue | $9.5M | -- | $5.7M | -- | $1.1M | |
| Gross Profit | $1M | -- | $765K | -- | $19K | |
| Operating Income | -$7.1M | -- | -$5.1M | -- | -$1.2M | |
| EBITDA | -$6.6M | -- | -$4.7M | -- | -$1.1M | |
| Diluted EPS | -$4.32 | -- | -$2.32 | -- | -$0.48 | |
| Period Ending | 2021-02-28 | 2022-02-28 | 2023-02-28 | 2024-02-28 | 2025-02-28 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $10.8M | $15.2M | $6.5M | -- | $6.2M | |
| Total Assets | $13.3M | $17.6M | $8.2M | -- | $7.4M | |
| Current Liabilities | $1.4M | $6.7M | $1.4M | -- | $1.6M | |
| Total Liabilities | $2.7M | $7.8M | $2.2M | -- | $1.8M | |
| Total Equity | $10.6M | $9.8M | $6M | -- | $5.5M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-02-28 | 2024-02-28 | 2025-02-28 | 2024-02-28 | 2025-02-28 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$8.8M | -- | -$4.2M | -- | -$1M | |
| Cash From Investing | -$88K | -- | -$61K | -- | -$4K | |
| Cash From Financing | $2.1M | -- | -- | -- | $1.7M | |
| Free Cash Flow | -$8.9M | -- | -$4.3M | -- | -$1M | |
BMRA
Sector
Market Cap
$8.8M
$33.9M
Price % of 52-Week High
34.06%
44.2%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.74%
1-Year Price Total Return
-26.7%
-40.43%
Beta (5-Year)
0.367
0.660
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$3.51
200-day SMA
Sell
Level
$3.53
Bollinger Bands (100)
Sell
Level
3 - 5.64
Chaikin Money Flow
Sell
Level
-40.3M
20-day SMA
Sell
Level
$3.74
Relative Strength Index (RSI14)
Sell
Level
40.47
ADX Line
Buy
Level
9.69
Williams %R
Neutral
Level
-72.4891
50-day SMA
Sell
Level
$4.50
MACD (12, 26)
Sell
Level
-0.29
25-day Aroon Oscillator
Sell
Level
-16
On Balance Volume
Neutral
Level
87.5M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-6.0593)
Sell
CA Score
(Annual)
Level (-1.4562)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (3)
Sell
Ohlson Score
Level (5.5823)
Buy
Piotroski F Score
(Annual)
Level (5)
Sell
Quality Ratio Score
Level (2)
Buy
Fundamental Score
Level (4)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Biomerica Inc is engaged in the development, manufacturing, and marketing of medical diagnostic products designed for the early detection and monitoring of chronic diseases and medical conditions. The company focuses on products for gastrointestinal diseases, food intolerances, diabetes, and certain esoteric tests. It operates in one segment namely, the design, development, marketing and sales of diagnostic kits. The majority of the company's revenue is earned from the Asia, and also has its presence in Europe, North America, Middle East and South America.
Stock Forecast FAQ
In the current month, BMRA has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The BMRA average analyst price target in the past 3 months is --.
-
Where Will Biomerica Stock Be In 1 Year?
According to analysts, the consensus estimate is that Biomerica share price will rise to -- per share over the next 12 months.
-
What Do Analysts Say About Biomerica?
Analysts are divided on their view about Biomerica share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Biomerica is a Sell and believe this share price will drop from its current level to --.
-
What Is Biomerica's Price Target?
The price target for Biomerica over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is BMRA A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Biomerica is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of BMRA?
You can purchase shares of Biomerica via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Biomerica shares.
-
What Is The Biomerica Share Price Today?
Biomerica was last trading at $3.54 per share. This represents the most recent stock quote for Biomerica. Yesterday, Biomerica closed at $3.46 per share.
-
How To Buy Biomerica Stock Online?
In order to purchase Biomerica stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is BYD a Threat To Tesla Shareholders?
BYD (OTC:BYDDY) has rocketed to the top of China’s booming…
CVX Vs XOM Stock, Which Energy Play Is Best?
Chevron (NYSE:CVX) and Exxon Mobil (NYSE:XOM) are two of the…
Stock Ideas
Buy
70
Is MSFT Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 37x
Sell
39
Is AAPL Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 32x
Buy
63
Is NVDA Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 40x
Alerts
Buy
99
DAVE alert for May 9
Dave [DAVE] is up 6.89% over the past day.
Buy
52
QDEL alert for May 9
QuidelOrtho [QDEL] is down 0.96% over the past day.
Buy
61
TPC alert for May 9
Tutor Perini [TPC] is up 6.9% over the past day.
